📊 TBPH Key Takeaways
Is Theravance Biopharma, Inc. (TBPH) a Good Investment?
Theravance demonstrates exceptional cash generation ($238.5M OCF) and revenue growth (+66.9% YoY) with a fortress balance sheet ($167.8M cash, zero debt). However, negative operating income (-3.4% margin) indicates core operations are not yet profitable, with net income appearing driven by non-operating gains that may not be sustainable.
Why Buy Theravance Biopharma, Inc. Stock? TBPH Key Strengths
- Exceptional cash generation: $238.5M operating cash flow on $107.5M revenue signals strong underlying business fundamentals
- Fortress balance sheet: $167.8M cash, zero debt, 10.93x current ratio provides significant financial flexibility
- Strong revenue growth: 66.9% YoY growth indicates successful commercialization or new partnerships
- Excellent returns: 35.7% ROE and 21.8% ROA demonstrate efficient capital deployment
TBPH Stock Risks: Theravance Biopharma, Inc. Investment Risks
- Operating income is negative (-3.4% margin), indicating core business operations are not yet profitable
- Net income driven by non-operating gains, suggesting reliance on one-time events rather than operational earnings sustainability
- Pharmaceutical sector inherent risks: regulatory, clinical trial failures, patent expirations, and product pipeline execution
- Disconnect between operating income and net income reduces visibility into true operational performance
Key Metrics to Watch
- Operating margin trend and path to profitability
- Source and sustainability of non-operating gains
- Operating cash flow trajectory relative to revenue growth
- R&D efficiency and drug pipeline advancement status
- Cash burn rate and runway given current cash position
Theravance Biopharma, Inc. (TBPH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 221.9% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 10.93x current ratio provides a solid financial cushion.
TBPH Profit Margin, ROE & Profitability Analysis
TBPH vs Healthcare Sector: How Theravance Biopharma, Inc. Compares
How Theravance Biopharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Theravance Biopharma, Inc. Stock Overvalued? TBPH Valuation Analysis 2026
Based on fundamental analysis, Theravance Biopharma, Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Theravance Biopharma, Inc. Balance Sheet: TBPH Debt, Cash & Liquidity
TBPH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Theravance Biopharma, Inc.'s revenue has grown significantly by 46% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.24 indicates the company is currently unprofitable.
TBPH Revenue Growth, EPS Growth & YoY Performance
TBPH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $16.9M | $3.6M | $0.07 |
| Q2 2025 | $14.3M | -$16.5M | $-0.34 |
| Q1 2025 | $14.5M | -$11.7M | $-0.24 |
| Q3 2024 | $15.7M | -$9.0M | $-0.17 |
| Q2 2024 | $13.7M | -$15.6M | $-0.28 |
| Q1 2024 | $10.4M | -$11.7M | $-0.24 |
| Q3 2023 | $12.5M | -$9.0M | $-0.17 |
| Q2 2023 | $11.1M | -$8.2M | $-0.11 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Theravance Biopharma, Inc. Dividends, Buybacks & Capital Allocation
TBPH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Theravance Biopharma, Inc. (CIK: 0001583107)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_100419.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_100414.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_100411.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_100454.xml | View → |
| Mar 30, 2026 | 8-K | tm2610626d1_8k.htm | View → |
❓ Frequently Asked Questions about TBPH
What is the AI rating for TBPH?
Theravance Biopharma, Inc. (TBPH) has an AI rating of BUY with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TBPH's key strengths?
Claude: Exceptional cash generation: $238.5M operating cash flow on $107.5M revenue signals strong underlying business fundamentals. Fortress balance sheet: $167.8M cash, zero debt, 10.93x current ratio provides significant financial flexibility.
What are the risks of investing in TBPH?
Claude: Operating income is negative (-3.4% margin), indicating core business operations are not yet profitable. Net income driven by non-operating gains, suggesting reliance on one-time events rather than operational earnings sustainability.
What is TBPH's revenue and growth?
Theravance Biopharma, Inc. reported revenue of $107.5M.
Does TBPH pay dividends?
Theravance Biopharma, Inc. does not currently pay dividends.
Where can I find TBPH SEC filings?
Official SEC filings for Theravance Biopharma, Inc. (CIK: 0001583107) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TBPH's EPS?
Theravance Biopharma, Inc. has a diluted EPS of $2.06.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TBPH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Theravance Biopharma, Inc. has a BUY rating with 68% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is TBPH stock overvalued or undervalued?
Valuation metrics for TBPH: ROE of 35.7% (sector avg: 15%), net margin of 98.5% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy TBPH stock in 2026?
Our dual AI analysis gives Theravance Biopharma, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is TBPH's free cash flow?
Theravance Biopharma, Inc.'s operating cash flow is $238.5M, with capital expenditures of $42.0K. FCF margin is 221.9%.
How does TBPH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 98.5% (avg: 12%), ROE 35.7% (avg: 15%), current ratio 10.93 (avg: 2).
Why is TBPH's return on equity (ROE) so high?
Theravance Biopharma, Inc. has a return on equity of 35.7%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 98.5% net margin.